Please login to the form below

Not currently logged in
Email:
Password:

statutory medicines

This page shows the latest statutory medicines news and features for those working in and with pharma, biotech and healthcare.

No further price cut for non-PPRS drugs in UK

No further price cut for non-PPRS drugs in UK

No further price cut for non-PPRS drugs in UK. But industry concerned over long-term plan for statutory medicines on the NHS. ... The DH announced in November 2013 that it would reduce the cost of these statutory medicines by 15% as part of wider drug

Latest news

  • No further price cut for non-PPRS drugs in UK No further price cut for non-PPRS drugs in UK

    No further price cut for non-PPRS drugs in UK. But industry concerned over long-term plan for statutory medicines on the NHS. ... The DH announced in November 2013 that it would reduce the cost of these statutory medicines by 15% as part of wider drug

  • ABPI Code updates come into effect ABPI Code updates come into effect

    There is also a grace period for the revised statutory scheme, which covers medicines that pharma companies choose to exclude from the voluntary, but more well-used. ... medicines). Bookings for these exams will be through a new website: http://exams.abpi

  • NHS medicine spend to remain flat for two years NHS medicine spend to remain flat for two years

    to face a price cut on branded medicines to stick to the revised budget. ... In addition to the PPRS announcement, the DH also published details of its plans for statutory medicines - branded drugs sold by companies who do not sign up to the voluntary

  • UK brings in new medicines regulations

    UK brings in new medicines regulations. Human Medicines Regulations 2012 aim to simplify existing legislation. ... The Human Medicines Regulations 2012 replaces much of the Medicines Act and around 200 statutory instruments and will, the Medicines and

  • UK’s MHRA seeks views on scheme to provide early access to medicines

    UK’ s MHRA seeks views on scheme to provide early access to medicines. ... The voluntary, on-statutory scheme will be limited to medicines that represent a “ significant advance in treatment in an area of unmet need”, said the MHRA, and only one or

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics